BioImage Targets Signaling Proteins


Copenhagen - The drug discovery company BioImage A/S focuses on identifying new therapeutics against known signaling targets in order to modulate the activity of signaling pathways, using Redistribution®-based pathway screening. In response to pharmacologic stimuli such as test compounds, the intracellular location of many proteins undergoes distinctive changes. The Redistribution® technology enables the monitoring of protein translocations in living cells as a primary assay readout by tagging relevant targets with Green Fluorescent Protein (GFP) and using high throughput imaging to quantify the responses.
Assays for Monitoring
Protein Translocation
Modes of action that are detected by Redistribution® include conventional inhibitors of catalytic activity, as well as compounds that target protein localization domains, adaptor/scaffolding molecules without inherent catalytic activity, compounds that induce conformational change of the target, and compounds that inhibit protein-protein interactions. BioImage has active internal early discovery projects which aim to advance inflammation and oncology lead compounds to a preclinical stage prior to partnership. The company profiles lead compounds for clients through panels of existing Redistribution® assays and develops custom assays for client targets. It can perform primary screens and pathway screening for client libraries and access to Redistribution® technology through licensing.
BioImage A/S
Moerkhoej Bygade 28
2860 Soeborg
Tel.: +45-(0)4443-34 44
Fax: +45-(0)4443-75 05



Bagsvaerd/Bangalore – Danish Novozymes A/S has begun a new collaboration with Indian Sea6 Energy. The companies will jointly develop enzymes to convert seaweed-based carbohydrates to sugar, which can then be fermented to produce...



Prague/Turku/Copenhagen – Danish pharmaceutical company H. Lundbeck A/S yesterday unveiled clinical data on its potential blockbuster drug nalmefene at the 2012 European Congress of Psychiatry clinical in Prague. While Lundbeck...



Copenhagen – With the in vitro proof of concept for an undisclosed antibody target, Genmab A/S has reached the second milestone in its collaboration with H. Lundbeck A/S. Genmab will now receive a €1m payment. Under the...



Copenhagen/Bangalore – Biofuels need reliable sources of biomass. Novozymes now looks to the ocean to secure biomass. The Danish enzyme specialist announced an exploratory research agreement with Sea6 Energy from India. The...



Copenhagen – Hellsinn Healthcare has successfully completed a phase Ib trial in Europe with Zealand Pharma’s GLP-2 (glucagone-like peptide 2) peptide antagonist Elsiglutide (ZP1846). The completion of the study, which was...



Copenhagen - An alliance of giants will take a thorough look into biofuels for the maritime sector. The leading enzyme producer Novozymes will team up with parts of the Danish shipping industry, including the world’s largest...



Copenhagen/Paris – Danish biopharma­ceuticals company Zealand Pharma A/S has received some positive news. Ever since French partner Sanofi Aventis submitted a marketing authorisation application for Lyxumia (lixisenatide) in...



Copenhagen/Paris - The cooperation between Danish biopharmaceutical company Zealand Pharma and French drugmaker Sanofi has borne its first fruit. Sanofi has submitted a marketing authorisation application for Lyxumia...



Copenhagen/Ingelheim – Danish HTS expert Nuevolution A/S has signed a license agreement with drugmaker Boeh­ringer Ingelheim (BI). The German pharma company will use Nuevolution’s proprietary Chemetics drug discovery technology...



Bagsværd - Novo Nordisk is investing around €134m in a new corporate centre in the Copenhagen suburb Bagsværd. The new office premises will concentrate the top management and 1,100 administrative employees which are currently...

Displaying results 1 to 10 out of 194

1-10 Next >

© 2007-2015 BIOCOM


All Events


Product of the week


Current issue

All issues